Seek Returns logo

ASND vs. ZBH: A Head-to-Head Stock Comparison

Updated

Here’s a clear look at ASND and ZBH, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.

Company Overview

ZBH stands out with 18.35 billion USD in market value—about 1.92× ASND’s market cap of 9.55 billion USD.

ZBH carries a higher beta at 0.78, indicating it’s more sensitive to market moves, while ASND remains steadier at 0.40.

ASND trades as an ADR, giving U.S. investors a simple on-ramp to its foreign shares, while ZBH remains a standard domestic listing.

SymbolASNDZBH
Company NameAscendis Pharma A/SZimmer Biomet Holdings, Inc.
CountryDKUS
SectorHealthcareHealthcare
IndustryBiotechnologyMedical - Devices
CEOMr. Jan Moller MikkelsenMr. Ivan Tornos
Price158.1 USD92.74 USD
Market Cap9.55 billion USD18.35 billion USD
Beta0.400.78
ExchangeNASDAQNYSE
IPO DateJanuary 28, 2015July 25, 2001
ADRYesNo

Performance Comparison

This chart compares the performance of ASND and ZBH over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).

Hover over the lines to see the investment’s value and total return (%) at specific dates.

Data is adjusted for dividends and splits.

Valuation Metrics Comparison

The section examines key financial ratios to assess the valuation of ASND and ZBH based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.

  • ASND posts a negative P/E of -24.55, reflecting last year’s net loss, while ZBH at 25.75 signals healthy earnings.
  • ASND posts a negative forward PEG of -2.23, hinting at anticipated earnings decline, whereas ZBH at 3.45 has projections for stable or growing earnings.
  • ASND has a negative P/B ratio of -44.20, indicating its liabilities exceed assets (negative equity). ZBH, with a P/B of 1.35, maintains positive shareholder equity.
  • ASND has a negative Price-to-Free Cash Flow ratio of -27.43, signaling it consumed more cash than it produced over the last year—an important liquidity warning. In contrast, ZBH (P/FCF 12.77) indicates positive free cash flow generation.
SymbolASNDZBH
Price-to-Earnings Ratio (P/E, TTM)-24.5525.75
Forward PEG Ratio (TTM)-2.233.45
Price-to-Sales Ratio (P/S, TTM)22.892.38
Price-to-Book Ratio (P/B, TTM)-44.201.35
Price-to-Free Cash Flow Ratio (P/FCF, TTM)-27.4312.77
EV-to-EBITDA (TTM)-35.7413.49
EV-to-Sales (TTM)23.783.14
EV-to-Free Cash Flow (TTM)-28.5016.80

Dividend Comparison

ASND offers a 0% dividend yield, suggesting it may be reinvesting available cash back into the business for future growth, while ZBH provides a 1.04% dividend yield, giving investors a steady income stream.

SymbolASNDZBH
Dividend Yield (TTM)0.00%1.04%

Financial Strength Metrics Comparison

This section dives into the financial resilience of ASND and ZBH, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.

  • ASND’s quick ratio of 0.71 suggests it may struggle to cover immediate liabilities without selling inventory or raising cash, whereas ZBH at 1.97 maintains a comfortable buffer of liquid assets.
  • ASND has negative equity (debt-to-equity ratio -4.46), an unusual warning sign, while ZBH at 0.52 maintains a conventional debt-to-equity balance.
  • With negative EBIT (-3.72), ASND cannot cover its interest payments. ZBH, with an interest coverage of 6.00, meets its interest obligations.
SymbolASNDZBH
Current Ratio (TTM)1.043.30
Quick Ratio (TTM)0.711.97
Debt-to-Equity Ratio (TTM)-4.460.52
Debt-to-Assets Ratio (TTM)0.800.32
Interest Coverage Ratio (TTM)-3.726.00